medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2008, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2008; 7 (1)


Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease

Uribe M; Zamora-Valdés D; Moreno-Portillo M; Bermejo-Martínez L; Pichardo-Bahena R; Baptista-González HA; Ponciano-Rodríguez G; Uribe MH; Medina-Santillán R; Méndez-Sánchez N

Idioma: Español
Referencias bibliográficas: 24
Paginas: 67-71
Archivo PDF: 112.88 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mendez-Sanchez N, Arrese M, Zamora-Valdes D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 2007; 27: 423-33.

  2. Day CP, James OF. Steatohepatitis: a tale of two «hits»? Gastroenterology 1998; 114: 842-5.

  3. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9.

  4. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.

  5. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences. J Hepatol 2007; 47: 142-56.

  6. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.

  7. Mendez-Sanchez N, Chavez-Tapia NC, Villa AR, et al. Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol 2005; 11: 1737-41.

  8. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87: 2988-2991.

  9. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495-522.

  10. Mendez-Sanchez N, Chavez-Tapia NC, Uribe-Esquivel M. [Ghrelin and the gastro-hypothalamic axis]. Gac Med Mex 2006; 142: 49-58.

  11. Marchesini G, Pagotto U, Bugianesi E, et al. Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. J Clin Endocrinol Metab 2003; 88: 5674-9.

  12. Barazzoni R, Bosutti A, Stebel M, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2005; 288: E228-35.

  13. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111: 697-716.

  14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.

  15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.

  16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94(9): 2467-74.

  17. Mendez-Sanchez N, Chavez-Tapia NC, Uribe M. [An update on non-alcoholic fatty liver disease]. Rev Invest Clin 2004; 56: 72-82.

  18. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.

  19. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21: 105-13.

  20. Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-54.

  21. Streetz KL, Luedde T, Manns MP, Trautwein C. Interleukin 6 and liver regeneration. Gut 2000; 47: 309-12.

  22. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003; 278: 13740-6.

  23. Hong F, Radaeva S, Pan HN, Tian Z, Veech R, Gao B. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 2004; 40: 933-41.

  24. Yoda-Murakami M, Taniguchi M, Takahashi K, et al. Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver. Biochem Biophys Res Commun 2001; 285: 372-7.




2020     |     www.medigraphic.com